Simon Thacker

ORCID: 0000-0002-3203-1392
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Neurological Disease Mechanisms and Treatments
  • Alzheimer's disease research and treatments
  • Socioeconomic Development in MENA
  • Diabetes Treatment and Management
  • Advanced Neuroimaging Techniques and Applications
  • Advanced MRI Techniques and Applications
  • Global Educational Reforms and Inequalities
  • Diet and metabolism studies
  • Adipose Tissue and Metabolism
  • Metabolism, Diabetes, and Cancer
  • Neurological Disorders and Treatments
  • Cancer-related cognitive impairment studies
  • Regional Development and Policy
  • Frailty in Older Adults
  • Socioeconomic Development in Asia
  • Education and Islamic Studies
  • Cerebrovascular and Carotid Artery Diseases
  • Education Systems and Policy
  • Stroke Rehabilitation and Recovery
  • Crop Yield and Soil Fertility
  • Psychiatric care and mental health services
  • Birth, Development, and Health
  • Optical Imaging and Spectroscopy Techniques
  • Human Resource Development and Performance Evaluation

Derbyshire Community Health Services NHS Foundation Trust
2019-2024

Canterbury Christ Church University
2020

Dublin City University
2020

World Education
2020

National Health Service
2018

Queen's Medical Centre
1996

Emory University
1986-1993

Grady Memorial Hospital
1986

Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity cerebral glucose uptake, increasing the proliferation neuronal progenitor cells. The primary objective study to evaluate change metabolic rate after 12 months treatment with participants compared those...

10.1186/s13063-019-3259-x article EN cc-by Trials 2019-04-03

Abstract Background Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral resistance on aetiopathogenesis in non-diabetic patients still debated. Here we evaluated the influence glucose metabolism, grey matter volume white lesions (WMLs) subjects. Methods In total, 130 subjects underwent MRI [18F]FDG PET scans with arterial cannula insertion radioactivity measurement. T1 Volumetric FLAIR sequences were acquired...

10.1186/s13195-021-00784-w article EN cc-by Alzheimer s Research & Therapy 2021-02-17

To determine the effectiveness of an exercise and functional activity therapy intervention in adults with early dementia or mild cognitive impairment compared usual care.Randomised controlled trial.Participants' homes communities at five sites United Kingdom.365 who were living home, family members carers.The intervention, Promoting activity, Independence, Stability Early Dementia (PrAISED), was a specially designed, specific, rehabilitation programme focusing on strength, balance, physical...

10.1136/bmj-2023-074787 article EN cc-by BMJ 2023-08-29

Abstract Background Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue licensed for the treatment of type 2 diabetes. Preclinical evidence in transgenic models Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, increasing proliferation neuronal progenitor cells. Methods ELAD 12‐month, multi‐centre, randomised, double‐blind, placebo‐controlled, phase IIb trial...

10.1002/alz.057848 article EN Alzheimer s & Dementia 2021-12-01

Abstract Background Preclinical evidence in transgenic models of Alzheimer’s disease (AD) suggests that liraglutide, a GLP1 analogue, exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and insulin resistance, increasing the proliferation neuronal progenitor cells. ELAD is 12‐month, multi‐centre, randomised, double‐blind, placebo‐controlled, phase IIb trial liraglutide participants with mild to moderate AD conducted at 24 centres UK. Method As part...

10.1002/alz.080538 article EN Alzheimer s & Dementia 2023-12-01

We investigated the effects of acute food deprivation on rates glucose metabolism and lactate production by epididymal fat cells isolated from 2- 8-mo-old Wistar rats in one three nutritional states: fed ad libitum, restricted to 50% or fasted for 48 h. Food restriction did not affect total basal but significantly altered its pattern. In small 2-mo-old rats, donor's led decreased insulin-stimulated oxidation fatty acid synthesis increased production, which 4% metabolized 62% rats. large...

10.1152/ajpendo.1987.253.4.e336 article EN AJP Endocrinology and Metabolism 1987-10-01

The metabolic state occurring with refeeding after fasting is characterized by the rapid restoration of hepatic glycogen. Recent evidence suggests that a main substrate for glycogenesis lactate. Because adipose tissue an active site lactate production increases fasting, we examined magnitude and duration isolated adipocytes from three depots rats fasted 48 h then refed up to 96 h. data show results in markedly elevated rate adipocyte production, which increased 3-9% total glucose metabolized...

10.1152/ajpendo.1990.259.6.e865 article EN AJP Endocrinology and Metabolism 1990-12-01

Abstract Background Dementia is associated with frailty leading to increased risks of falls and hospitalisations. Interventions are required maintain functional ability, strength balance. Design Multi-centre parallel group randomised controlled trial, embedded process evaluation. Procedures were adapted during the COVID-19 pandemic. Participants People mild dementia or cognitive impairment (MCI), living at home, a family member carer. Objectives To determine effectiveness an exercise...

10.1101/2022.12.20.22283699 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2022-12-20

We studied the effect of variable isolated fat cell concentrations (from 0.17 to 1.25 x 10(6) cells/ml) on rate and pattern basal insulin-stimulated glucose metabolism by rat epididymal cells. Cell concentration did not affect total utilization, but high increased absolute relative conversion CO2 glyceride-fatty acids two- threefold decreased lactate, pyruvate, glyceride-glycerol when compared with values observed at low concentration. When effects adenosine deaminase (ADA)...

10.1152/ajpendo.1993.264.3.e361 article EN AJP Endocrinology and Metabolism 1993-03-01

Abstract Background Alzheimer’s disease is a devastating neurodegenerative disorder with complex pathogenesis. One main pathological feature utilised in diagnosis neurodegeneration or neuronal injury, which reflected reductions cerebral glucose metabolism measured by [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). Here we evaluated the involvement of glial reactivity magnetic resonance spectroscopy (MRS) and blood flow arterial spin labelling (ASL) on [18F]FDG PET as...

10.1002/alz.088897 article EN cc-by Alzheimer s & Dementia 2024-12-01

Blood glucose-monitoring techniques originally developed to aid outpatient management of diabetic patients are now being used facilitate hospital care. However, applications in hyperglycemic have been limited because many glucose-oxidase strips and meters respond only glucose values ≤ 400 mg/dl. We asked if prior dilution blood samples would permit reliable estimations. Ten consecutive decompensated (age 35–73, 506–879, HCO3 12–28) had determinations done simultaneously by the laboratory...

10.2337/diacare.9.1.77 article EN Diabetes Care 1986-01-01

Abstract Background Cerebral metabolic rate of glucose (CMRglc) can be measured with fluorodeoxyglucose (FDG) positron emission tomography (PET) using arterial blood sampling. However, sampling is an invasive methodology for subjects. Standard uptake value (SUV) a non‐invasive method to assess the cerebral metabolism. Here we evaluate relationship between semi‐quantitative measurements such as SUV and Pons ratio quantitative measurement Spectral analysis (SA) in order their surrogate use...

10.1002/alz.046068 article EN Alzheimer s & Dementia 2020-12-01

Abstract Background Brain atrophy can be reliably measured through volumetric analysis of structural MRI and is a valid biomarker neurodegeneration in Alzheimer’s disease (AD) pathology 1 . The Disease Assessment Scale‐Cognitive subscale (ADAS‐Cog12) neuropsychological test designed to assess the level cognitive dysfunction AD within domains such as memory 2 This study aimed relationship between brain ADAS‐Cog12 score patients with AD. Methods 172 mild‐to‐moderate (Age range 51‐58, Mean=71,...

10.1002/alz.046004 article EN Alzheimer s & Dementia 2020-12-01
Coming Soon ...